The ability to manipulate the murine genome by the introduction of foreign genes or the modification of endogenous genes has offered researchers a potent tool to establish animal models for human diseases. The overall goal of the Transgenic Core is to allow SPORE investigators to manipulate the murine genome to create animal models for the investigation of the development of prostate cancer. Once animal models are established, SPORE investigators can use these animals to develop and evaluate the potential of therapeutic agents for the cure and prevention of prostate cancer. During the last three years the Transgenic Core has produced transgenics by the microinjection of DNA into the pronucleus of th one cell mouse embryo. First, the Transgenic Core produced mice to evaluate the potential of specific promoter elements in targeting gene expression to the prostate. Once the investigators identified the DNA elements that would target gene expression to the prostate, the Transgenic Core has generated transgenic animals with oncogenes under the control of these prostate specific elements. In doing so, the Transgenic Core has produced transgenic mice which develop prostate cancer. The Transgenic Core will continue to produce transgenic mice by DNA microinjection in order to allow investigators to evaluate the usefulness of potential models for prostate cancer. In addition, the Transgenic Core will expand to allow investigators to take advantage of Embryonic Stem Cell technology to investigate the role of specific regulatory proteins in the development of prostate cancer. The Transgenic Core will also continue to serve as a resource to preserve the animal models already established by SPORE investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058204-07S2
Application #
6296061
Study Section
Project Start
1999-06-01
Project End
2000-05-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biological correlates of prostate cancer perineural invasion diameter. Hum Pathol 45:1365-9
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biologic correlates and significance of axonogenesis in prostate cancer. Hum Pathol 45:1358-64
Sonpavde, Guru; Wang, Mingjun; Peterson, Leif E et al. (2014) HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs 32:235-242
Nakka, Manjula; Agoulnik, Irina U; Weigel, Nancy L (2013) Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 45:763-72
Ding, Yi; He, Dandan; Florentin, Diego et al. (2013) Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res 19:6101-11
Feng, Shu; Dakhova, Olga; Creighton, Chad J et al. (2013) Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 73:2551-62
Yang, Feng; Zhang, Yongyou; Ressler, Steven J et al. (2013) FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res 73:3716-24
Yang, Guang; Goltsov, Alexei A; Ren, Chengzhen et al. (2012) Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10:218-29
Sonpavde, Guru; Thompson, Timothy C; Jain, Rajul K et al. (2011) GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17:7174-82
Wang, Jianghua; Cai, Yi; Shao, Long-Jiang et al. (2011) Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res 71:1325-33

Showing the most recent 10 out of 262 publications